Browse All

Current Filters

CLEAR FILTER x

TITLE

Evidence for Survival Benefit in ALS with CNM-Au8 Treatment Across Three Study Populations

Author:Berry, James   Maragakis, Nicholas   Paganoni, Sabrina   Quintana, Melanie   Macklin, Eric   Saville, Benjamin   Andrews, Jinsy   Shefner, Jeremy   Detry, Michelle   Menon, Parvathi   Huynh, William   Mahoney, Colin   Stommel, Elijah   Hall, Meghan   Connolly, Mariah   Kittle, Gale   Chase, Marianne   Sherman, Alexander   Yu, Hong   Pothier, Lindsay   Drake, Kristin   Chibnik, Lori   Bind, Marie-Abele   Vestrucci, Matteo   Glanzman, Robert   Hotchkin, Michael   Vucic, Steve   Kiernan, Matthew   Cudkowicz, Merit   Study Group, HEALEY ALS Platform Trial   Investigators, RESCUE-ALS   

Session Name:P8: Neuromuscular Disease: Amyotrophic Lateral Sclerosis 1  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:P8.004  

Author Institution:Massachusetts General Hospital, Boston, MA  Johns Hopkins University School of Medicine, Baltimore, MD  Berry Consultants, San Francisco, CA  MGH Biostatistics Center, Boston, MA  Columbia University Medical Center, New York, NY  Barrow Neurological Institute, Phoenix, AZ  Westmead Public Hospital, Sydney, Australia  Prince of Wales Hospital, Randwick, Australia  University of Sydney, Sydney, Australia  Dartmouth-Hitchock Med Ctr/Dept of Neuro, Lebanon, NH  Massachusetts General Hospital, Charlestown, MA  Clene Nanomedicine Inc, Holladay, UT  Clene Nanomedicine, Inc., Salt Lake City, UT  Brain and Mind Centre, Sydney, Australia  HEALEY ALS Platform Trial, Boston, MA  RESCUE-ALS Trial, Sydney, Australia  

A Randomized Double-Blind Study to Assess the Skin Irritation and Sensitization Potential of Once-Weekly Donepezil Transdermal Delivery System